MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

C. Mircea S. Tesileanu, Thierry Gorlia, EORTC Brain Tumor Grp, the CATNON investigators, Vassilis Golfinopoulos, Pim J. French, Martin J. Van Den Bent*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

3 Citations (Scopus)
5 Downloads (Pure)
Original languageEnglish
Pages (from-to)665-667
Number of pages3
Issue number4
Early online date31 Jan 2022
Publication statusPublished - 1 Apr 2022

Bibliographical note

The CATNON study was funded by Merck, Sharp and Dohme (MSD) formerly Schering-Plough by an educational grant and by the provision of temozolomide. The clinical study was also supported by the NRG (grants U10CA180868 and U10CA180822), Cancer Research UK grant CRUK/07/028, and Cancer Australia (project grants 1026842 and 1078655). The molecular study was funded by grant GN-000577 from The Brain Tumour Charity, grant 10685 from the Dutch Cancer Society, and financial support from the Vereniging Heino “Strijd van Salland”

Cite this